Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma

BACKGROUND: Immune checkpoint inhibitors have improved survival in advanced stage melanoma patients. Rates of new primary melanomas (NPM) in patients with prior melanoma have been reported to be as high as 12%. Little is currently known regarding the frequency or characteristics of NPMs occurring in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennington, Thomas E, Zhao, Cathy Yunjia, Colebatch, Andrew J, Fernandez‐Peñas, Pablo, Guitera, Pascale, Burke, Hazel, Scolyer, Richard A, Menzies, Alexander M, Carlino, Matteo S, Lo, Serigne, Long, Georgina V, Saw, Robyn PM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303670/
https://www.ncbi.nlm.nih.gov/pubmed/35188271
http://dx.doi.org/10.1111/ajd.13807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303670/
https://www.ncbi.nlm.nih.gov/pubmed/35188271
http://dx.doi.org/10.1111/ajd.13807

Ejemplares similares